Axsome Therapeutics (AXSM) Invested Capital (2016 - 2026)

Axsome Therapeutics (AXSM) has 11 years of Invested Capital data on file, last reported at $11.2 million in Q1 2026.

• For the quarter ending Q1 2026, Invested Capital fell 93.81% year-over-year to $11.2 million; the trailing twelve-month figure through Mar 2026 stood at $371.2 million (down 48.45% YoY), and the FY2025 full-year result was $120.0 million, down 33.33% from the prior year.
• Invested Capital declined to $11.2 million in Q1 2026, from $120.0 million in the prior quarter.
• In the past five years, Invested Capital ranged from a high of $180.0 million in Q2 2023 to a low of $11.2 million in Q1 2026.
• A 5-year average of $135.1 million and a median of $150.0 million in 2023 frame the typical range for Invested Capital.
• Across the five-year window, Invested Capital surged 200.0% in 2023 and sank 93.81% in 2026, its largest moves.
• Tracing AXSM's Invested Capital over 5 years: stood at $95.0 million in 2022, then soared by 89.47% to $180.0 million in 2023, then changed by 0.0% to $180.0 million in 2024, then sank by 33.33% to $120.0 million in 2025, then slumped by 90.71% to $11.2 million in 2026.
• Business Quant data shows AXSM's Invested Capital at $11.2 million in Q1 2026, $120.0 million in Q4 2025, and $120.0 million in Q3 2025.